NCT06790602View on ClinicalTrials.gov

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Pancreatic Ductal Adenocarcinoma (mPDAC)

Interventions

DRUG

Cemiplimab Plus Gemcitabine

Cemiplimab Plus Gemcitabine

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of California, San Diego

OTHER